Aaron I. Davis - Net Worth and Insider Trading

Aaron I. Davis Net Worth

The estimated net worth of Aaron I. Davis is at least $86.6 Billion dollars as of 2024-05-12. Aaron I. Davis is the Director, 10% Owner of Odonate Inc and owns about 5,052,842 shares of Odonate Inc (ODTC) stock worth over $86.4 Billion. Aaron I. Davis is the Director, 10% Owner of Mirati Therapeutics Inc and owns about 2,116,242 shares of Mirati Therapeutics Inc (MRTX) stock worth over $124 Million. Aaron I. Davis is also the Director of ITeos Therapeutics Inc and owns about 2,154,058 shares of ITeos Therapeutics Inc (ITOS) stock worth over $38 Million. Besides these, Aaron I. Davis also holds Rain Oncology Inc (RAIN) . Details can be seen in Aaron I. Davis's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Aaron I. Davis has not made any transactions after 2022-11-04 and currently still holds the listed stock(s).

Transaction Summary of Aaron I. Davis

Aaron I. Davis Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aaron I. Davis owns 10 companies in total, including Odonate Inc (ODTCD) , PMV Pharmaceuticals Inc (PMVP) , and BCTG Acquisition Corp (BCTG) among others .

Click here to see the complete history of Aaron I. Davis’s form 4 insider trades.

Insider Ownership Summary of Aaron I. Davis

Ticker	Comapny	Transaction Date	Type of Owner
ODTCD	Odonate Inc	2021-11-19	director & 10 percent owner
PMVP	PMV Pharmaceuticals Inc	2020-09-24	10 percent owner
BCTG	BCTG Acquisition Corp	2020-09-02	director & Chief Executive Officer
		2023-08-23	other: See remarks
		2020-07-21	10 percent owner
		2023-08-11	other: See remarks
		2013-05-20	10 percent owner
		2023-05-22	director
		2023-08-11	other: See remarks
		2023-02-09	10 percent owner

Aaron I. Davis Latest Holdings Summary

Aaron I. Davis currently owns a total of 4 stocks. Among these stocks, Aaron I. Davis owns 5,052,842 shares of Odonate Inc (ODTC) as of November 19, 2021, with a value of $86.4 Billion and a weighting of 99.81%. Aaron I. Davis owns 2,116,242 shares of Mirati Therapeutics Inc (MRTX) as of January 8, 2019, with a value of $124 Million and a weighting of 0.14%. Aaron I. Davis also owns 2,154,058 shares of ITeos Therapeutics Inc (ITOS) as of May 11, 2022, with a value of $38 Million and a weighting of 0.04%. The other 1 stocks Rain Oncology Inc (RAIN) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Aaron I. Davis

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ODTC	Odonate Inc	2021-11-19	5,052,842	17,100.00	86,403,598,200
MRTX	Mirati Therapeutics Inc	2019-01-08	2,116,242	58.70	124,223,405
ITOS	ITeos Therapeutics Inc	2022-05-11	2,154,058	17.44	37,566,772
RAIN	Rain Oncology Inc	2022-11-04	2,147,212	1.21	2,598,127

Holding Weightings of Aaron I. Davis

Aaron I. Davis Form 4 Trading Tracker

According to the SEC Form 4 filings, Aaron I. Davis has made a total of 5 transactions in Odonate Inc (ODTC) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in Odonate Inc is the sale of 1,200,000 shares on November 19, 2021, which brought Aaron I. Davis around $2 Million.

According to the SEC Form 4 filings, Aaron I. Davis has made a total of 0 transactions in Mirati Therapeutics Inc (MRTX) over the past 5 years. The most-recent trade in Mirati Therapeutics Inc is the sale of 50,000 shares on January 8, 2019, which brought Aaron I. Davis around $2 Million.

According to the SEC Form 4 filings, Aaron I. Davis has made a total of 4 transactions in ITeos Therapeutics Inc (ITOS) over the past 5 years, including 2 buys and 2 sells. The most-recent trade in ITeos Therapeutics Inc is the sale of 663,000 shares on May 11, 2022, which brought Aaron I. Davis around $14 Million.

More details on Aaron I. Davis's insider transactions can be found in the Insider Trading History of Aaron I. Davis table.

Insider Trading History of Aaron I. Davis

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Aaron I. Davis Trading Performance

GuruFocus tracks the stock performance after each of Aaron I. Davis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Aaron I. Davis is 8.43%. GuruFocus also compares Aaron I. Davis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Aaron I. Davis within 3 months outperforms 6 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Aaron I. Davis's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Aaron I. Davis

Average Return

Average return per transaction

Outperforming Transactions

3 out of 10 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	14.85
Relative Return to S&P 500(%)	13.16

Aaron I. Davis Ownership Network

Ownership Network List of Aaron I. Davis

No Data

Ownership Network Relation of Aaron I. Davis

Aaron I. Davis Owned Company Details

What does Odonate Inc do?

Who are the key executives at Odonate Inc?

Aaron I. Davis is the director & 10 percent owner of Odonate Inc. Other key executives at Odonate Inc include 10 percent owner Ecor1 Capital, Llc , director & 10 percent owner Boxer Capital, Llc , and director & 10 percent owner & Chief Executive Officer Kevin C Tang .

Odonate Inc (ODTCD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Odonate Inc (ODTCD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Odonate Inc (ODTCD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Odonate Inc (ODTCD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Odonate Inc Insider Transactions

No Available Data

What does PMV Pharmaceuticals Inc do?

Who are the key executives at PMV Pharmaceuticals Inc?

Aaron I. Davis is the 10 percent owner of PMV Pharmaceuticals Inc. Other key executives at PMV Pharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , Chief Medical Officer Leila Alland , and SVP & Regulatory Affairs and QA Deepika Jalota .

PMV Pharmaceuticals Inc (PMVP) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in PMV Pharmaceuticals Inc (PMVP). Other recent insider transactions involving PMV Pharmaceuticals Inc (PMVP) include a net sale of 87,786 shares made by Orbimed Advisors Llc , a net sale of 6,291 shares made by Leila Alland , and a net sale of 4,104 shares made by Deepika Jalota .

In summary, during the past 3 months, insiders sold 0 shares of PMV Pharmaceuticals Inc (PMVP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 98,181 shares of PMV Pharmaceuticals Inc (PMVP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 98,181 shares.

PMV Pharmaceuticals Inc (PMVP)'s detailed insider trading history can be found in Insider Trading Tracker table.

PMV Pharmaceuticals Inc Insider Transactions

No Available Data

What does BCTG Acquisition Corp do?

Who are the key executives at BCTG Acquisition Corp?

Aaron I. Davis is the director & Chief Executive Officer of BCTG Acquisition Corp. Other key executives at BCTG Acquisition Corp include 10 percent owner Bctg Holdings, Llc , director & President Christopher Fuglesang , and COO and Secretary Andrew Ruel Ellis .

BCTG Acquisition Corp (BCTG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BCTG Acquisition Corp (BCTG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BCTG Acquisition Corp (BCTG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BCTG Acquisition Corp (BCTG)'s detailed insider trading history can be found in Insider Trading Tracker table.

BCTG Acquisition Corp Insider Transactions

No Available Data

What does ITeos Therapeutics Inc do?

Who are the key executives at ITeos Therapeutics Inc?

Aaron I. Davis is the other: See remarks of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include Chief Financial Officer Matthew Gall , other: See remarks Joseph Lewis , and other: See remarks Boxer Asset Management Inc. .

ITeos Therapeutics Inc (ITOS) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in ITeos Therapeutics Inc (ITOS). Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net sale of 350,000 shares made by Boxer Capital, Llc , and a net purchase of 5,000 shares made by Matthew Gall .

In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 345,000 shares.

ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

ITeos Therapeutics Inc Insider Transactions

No Available Data

What does Pandion Therapeutics Inc do?

Who are the key executives at Pandion Therapeutics Inc?

Aaron I. Davis is the 10 percent owner of Pandion Therapeutics Inc. Other key executives at Pandion Therapeutics Inc include director & 10 percent owner Daniel J. Becker , 10 percent owner Boxer Capital, Llc , and 10 percent owner Polaris Partners VIII, L.P. .

Pandion Therapeutics Inc (PAND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pandion Therapeutics Inc (PAND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pandion Therapeutics Inc (PAND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pandion Therapeutics Inc (PAND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pandion Therapeutics Inc Insider Transactions

No Available Data

What does Mirati Therapeutics Inc do?

Who are the key executives at Mirati Therapeutics Inc?

Aaron I. Davis is the other: See remarks of Mirati Therapeutics Inc. Other key executives at Mirati Therapeutics Inc include Sr. Vice President & Chief Scie Jamie Christensen , EVP & Chief Commercial Officer Benjamin Hickey , and Interim CFO Aaron Ondrey .

Mirati Therapeutics Inc (MRTX) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in Mirati Therapeutics Inc (MRTX). Other recent insider transactions involving Mirati Therapeutics Inc (MRTX) include a net sale of 16,852 shares made by Jamie Christensen , a net sale of 12,809 shares made by Benjamin Hickey , and a net sale of 81,996 shares made by Charles M Baum .

In summary, during the past 3 months, insiders sold 0 shares of Mirati Therapeutics Inc (MRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 126,645 shares of Mirati Therapeutics Inc (MRTX) were sold and 2,528,737 shares were bought by its insiders, resulting in a net purchase of 2,402,092 shares.

Mirati Therapeutics Inc (MRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirati Therapeutics Inc Insider Transactions

No Available Data

What does Aradigm Corp do?

Who are the key executives at Aradigm Corp?

Aaron I. Davis is the 10 percent owner of Aradigm Corp. Other key executives at Aradigm Corp include 10 percent owner Bleichroeder Lp , 10 percent owner First Eagle Investment Management, Llc , and 10 percent owner First Eagle Value In Biotechnology Master Fund, Ltd. .

Aradigm Corp (ARDMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aradigm Corp (ARDMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aradigm Corp (ARDMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aradigm Corp (ARDMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aradigm Corp Insider Transactions

No Available Data

What does Rain Oncology Inc do?

Who are the key executives at Rain Oncology Inc?

Aaron I. Davis is the director of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .

Rain Oncology Inc (RAIN) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 1,198,445 shares made by Kevin C Tang , a net sale of 995,000 shares made by Boxer Capital, Llc , and a net purchase of 122,000 shares made by Franklin M Berger .

In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,494,418 shares were bought by its insiders, resulting in a net purchase of 325,445 shares.

Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rain Oncology Inc Insider Transactions

No Available Data

What does Tango Therapeutics Inc do?

Who are the key executives at Tango Therapeutics Inc?

Aaron I. Davis is the other: See remarks of Tango Therapeutics Inc. Other key executives at Tango Therapeutics Inc include other: See remarks Mva Investors, Llc , 10 percent owner Third Rock Ventures Iv, L.p. , and See Remarks Douglas Barry .

Tango Therapeutics Inc (TNGX) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in Tango Therapeutics Inc (TNGX). Other recent insider transactions involving Tango Therapeutics Inc (TNGX) include a net purchase of 2,750,000 shares made by Boxer Capital, Llc , a net sale of 15,878 shares made by Adam Crystal , and a net sale of 210,000 shares made by Mva Investors, Llc .

In summary, during the past 3 months, insiders sold 372,500 shares of Tango Therapeutics Inc (TNGX) in total and bought 0 shares, with a net sale of 372,500 shares. During the past 18 months, 629,017 shares of Tango Therapeutics Inc (TNGX) were sold and 2,975,000 shares were bought by its insiders, resulting in a net purchase of 2,345,983 shares.

Tango Therapeutics Inc (TNGX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tango Therapeutics Inc Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Aaron I. Davis is the 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Chief Operating Officer Daniel Bensen , director & Chief Executive Officer Todd Harris , and 10 percent owner Mva Investors, Llc .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Aaron I. Davis made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 276,298 shares made by Daniel Bensen , a net sale of 252,175 shares made by Todd Harris , and a net sale of 265,568 shares made by Mva Investors, Llc .

In summary, during the past 3 months, insiders sold 19,797 shares of Tyra Biosciences Inc (TYRA) in total and bought 0 shares, with a net sale of 19,797 shares. During the past 18 months, 794,041 shares of Tyra Biosciences Inc (TYRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 794,041 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

Aaron I. Davis Mailing Address

Above is the net worth, insider trading, and ownership report for Aaron I. Davis. You might contact Aaron I. Davis via mailing address: 12860 El Camino Real, Suite 300, San Diego Ca 92130.

Discussions on Aaron I. Davis

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.